Allergan puts $45M upfront for Molecular Partners' long-lasting anti-VEGF in eye disease
This article was originally published in Scrip
Executive Summary
Demonstrating that it is serious about investing in retinal diseases, Allergan is paying $45 million upfront for global ophthalmic rights to Molecular Partners' MP0112, a molecule which recently completed two Phase I/IIa clinical trials for wet age-related macular degeneration (AMD) and diabetic macular oedema (DMO). For Molecular Partners, the deal represents the first commercial validation of its DARPin molecular platform, relatively small protein molecules with antibody-like binding properties.